FDG-PET provides physicians with survival predictions for patients with suspected atypical Parkinsonian syndrome.
FDG-PET can predict survival of patients with clinically suspected atypical Parkinsonian syndrome (APS), according to a study published in The Journal of Nuclear Medicine.
Researchers from Germany investigated the prognostic value of using FDG-PET compared with clinical diagnosis among patients with APS. Seventy-eight patients with suspected APS were enrolled in the study. All underwent initial FDG-PET imaging and were followed for 5.9 years. Of these patients, 44 were diagnosed with APS and 34 with Lewy body disease. Forty-four patients were still alive at 4.7 months (median) follow-up.
The results showed that patients who had been diagnosed with APS by PET or at one-year clinical follow-up had a median survival time of only 4.1 years, while the remaining patients, with Lewy body disease, had yet to reach median survival time.
The researchers concluded that use of FDG-PET provided an early predictor of survival in patients with clinically suspected APS. “This finding strongly supports the early inclusion of PET imaging in patient care,” they wrote.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.